Reaction
Intercepted Product Storage Error reporting signals
As of the last recalculation, Intercepted Product Storage Error appears in 3,369 FAERS reports alongside 39 co-occurring drug terms. The strongest observed disproportionality signal is ALTEPLASE (PRR 115.4).
Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.
| Drug | Co-reports | PRR | ROR |
|---|---|---|---|
| Alteplase | 259 | 115.4 | 117.4 |
| Faricimab | 67 | 52.1 | 52.5 |
| Dornase Alfa | 118 | 38.5 | 38.7 |
| Ado-Trastuzumab Emtansine | 36 | 26.7 | 26.8 |
| Tocilizumab | 401 | 24.5 | 24.6 |
| Omalizumab | 274 | 21.5 | 21.6 |
| Pertuzumab | 89 | 20.7 | 20.8 |
| Emicizumab | 34 | 17.2 | 17.2 |
| Obinutuzumab | 39 | 14.8 | 14.8 |
| Valganciclovir | 37 | 12.2 | 12.3 |
| Valganciclovir Hydrochloride | 37 | 12.2 | 12.3 |
| Ranibizumab | 46 | 10.8 | 10.9 |
| Atezolizumab | 65 | 10.5 | 10.5 |
| Ocrelizumab | 95 | 9.7 | 9.7 |
| Epoetin Alfa | 17 | 8.9 | 8.9 |
| Polatuzumab Vedotin | 12 | 7.6 | 7.6 |
| Trastuzumab | 78 | 7.2 | 7.2 |
| Bevacizumab | 118 | 6.1 | 6.1 |
| Dupilumab | 414 | 5.9 | 5.9 |
| Erenumab-Aooe | 46 | 5.2 | 5.2 |
| Leuprolide Acetate | 59 | 4.8 | 4.8 |
| Lanreotide Acetate | 6 | 4.7 | 4.7 |
| Agalsidase Beta | 7 | 4.7 | 4.7 |
| Insulin Glargine | 148 | 3.8 | 3.8 |
| Oseltamivir Phosphate | 15 | 3.8 | 3.8 |
| Sarilumab | 16 | 3.8 | 3.8 |
| Evolocumab | 95 | 3.7 | 3.7 |
| Cabotegravir | 4 | 3.1 | 3.1 |
| Vismodegib | 4 | 2.8 | 2.8 |
| Romosozumab-Aqqg | 6 | 2.7 | 2.7 |
| Abiraterone | 5 | 2.3 | 2.3 |
| Alirocumab | 9 | 2.2 | 2.2 |
| Fremanezumab-Vfrm | 4 | 2.2 | 2.2 |
| Enzalutamide | 20 | 2.1 | 2.1 |
| Galcanezumab-Gnlm | 10 | 2.0 | 2.0 |
| Tirzepatide | 49 | 1.9 | 1.9 |
| Pegfilgrastim | 26 | 1.6 | 1.6 |
| Pirfenidone | 9 | 1.4 | 1.4 |
| Aflibercept | 6 | 1.2 | 1.2 |